AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04579692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial treatment
Description: Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
Study NCT04700618 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
Study NCT04700618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
Study NCT05755685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)
Description: 5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
Study NCT04769544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with medial pivot tibial insert or symmetrical insert
Description: standard surgical implantation of total knee arthroplasty
Study NCT05205421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: Intravenous injection a single dose of RT-01
Study NCT06337331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 400mg/day PO Days -8 to -2
Study NCT06337331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m2/day IV Days -7 to -3
Study NCT06337331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/day IV Days -7 to -3
Study NCT06337331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2mg/kg/day IV Days -5 to -4
Study NCT06337331 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 200cGy Day -2
Study NCT04977583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Screening
Description: Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization.
Study NCT04977583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Referral - Resource Sheet
Description: Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
Study NCT04977583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Referral Assistance
Description: Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
Study NCT05253170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
Study NCT05253170 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionation
Description: Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
Study NCT05937191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide+Glucocorticoids treatment Group
Study NCT05937191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: Steroid Treatment
Study NCT05595356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session.
Study NCT05595356 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session.
Study NCT04854031 — intervention group
Intervention type: DEVICE
Intervention: Cochlear Implants
Description: Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
Study NCT05595356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: run-in sham transcranial direct current stimulation
Description: In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
Study NCT05595356 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: run-in sham transcranial direct current stimulation
Description: In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
Study NCT05595356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation video
Description: Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
Study NCT05595356 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation video
Description: Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
Study NCT05595356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutorial video
Description: Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
Study NCT05595356 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Tutorial video
Description: Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
Study NCT06214104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressur
Description: Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
Study NCT06125353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
Study NCT05362435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity-based wellness programs
Description: Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
Study NCT06244654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones
Description: After the VR group comes to the preoperative area and is evaluated, they will be asked to wear VR glasses and headphones. VR glasses and headphones were worn on the patient during peripheral nerve block applications and the operation. At the end of the operation, the VR glasses and headphones were removed and they were taken to the postoperative recovery room.
Study NCT06244654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No VR
Description: After evaluation of the patients taken to the preoperative area, routine peripheral nerve block application was performed without the use of VR glasses. VR glasses were not worn during the operation, as is the routine protocol. At the end of the surgery, they were taken to the postoperative recovery room.
Study NCT06320171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive neuromodulation
Description: Direct stimulation of the autonomic nervous system was achieved using Program 7 (P7) of the device, with a directional electrode positioned at the level of the C7 spinous process. P7 delivered a biphasic polarity current with oscillatory frequencies ranging from 1.92 to 14.29 Hz and variable intensities between 0.1 and 0.9 mA.
Study NCT06320171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group followed the same procedure, except that no current was applied during their 20-minute session.
Study NCT06555068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with Fulvestrant
Description: HRS-6209 in Combination with Fulvestrant
Study NCT06555068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with HRS-1358
Description: HRS-6209 in Combination with HRS-1358
Study NCT06555068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with Letrozole
Description: HRS-6209 in Combination with Letrozole
Study NCT06555068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209 in Combination with HRS-8080
Description: HRS-6209 in Combination with HRS-8080
Study NCT05550038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Compression ultrasound
Description: Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
Study NCT06576128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..
Study NCT06576128 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: parenteral local anesthesia
Description: As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2.5 mcg/kg
Description: 2.5 mcg/kg intrathecal
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2.75 mcg/kg
Description: 2.75 mcg/kg intrathecal
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 3 mcg/kg
Description: 3 mcg/kg intrathecal
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 3.25 mcg/kg
Description: 3.25 mcg/kg intrathecal
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 3.5 mcg/kg
Description: 3.5 mcg/kg intrathecal
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 4 mcg/kg
Description: 4 mcg/kg intrathecal
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 4.5 mcg/kg
Description: 4.5 mcg/kg intrathecal
Study NCT05552443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 5 mcg/kg
Description: 5 mcg/kg intrathecal
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum chemistry
Description: Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126).~Serum chemistries will include assessment of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase, glucose, sodium, potassium, blood urea nitrogen (BUN), and creatinine.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hematology
Description: Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126). The CBC assessment will include a red blood cells (RBC), hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MCV), white blood cells (WBC), neutrophils (% and abs.), lymphocytes (% and abs.), monocytes (% and abs.), eosinophils (% and abs.), basophils (% and abs.), large unstained cells (% and abs.).
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinalysis
Description: General urinalysis will be performed, by dipstick, during Screening, on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Cohort 2: Day 112) and follow-up EoS visits (arm 1: Day 91; Arm 2: Day 126).~Approximately 7-10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin urobilinogen and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: A complete physical examination will be performed at Screening, at all in-clinic study visits, and at the End of Study visit.~The physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~• Symptom-directed physical examinations will be performed at all other study visits.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: Vital sign measurements (body temperature, pulse and resting systolic and diastolic blood pressure) will be measured at Screening, at all in-clinic study visits, and at the End of Study visit. Vital signs will be measured in supine position after at least five minutes of rest.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG Test
Description: A 12-lead, resting, digital ECG will be taken for each participant during Screening, on Days 42 and 84 (for both arms), and on day 112 (Arm 2 only), after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT and QRS intervals and QTC. The report will be signed by the Investigator, who will record in the CRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the participants will be reviewed.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PK
Description: Blood PK analyses will be performed on ≥5ml blood collected in 5-mL K-EDTA CRO coded pre-labeled tubes, refrigerated immediately after collection. Plasma will be separated by centrifugation within 2h, and then frozen at -20C.~Blood samples will be collected pre-dose on Days 0, 7, and 84, as well as pre-dose at EoT (Arm 2: Day 112), and at any point during the in-clinic visit at EoS (Arm 1: Day 91; Arm 2: Day 126).
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IGA scoring
Description: Lesions severity will be assessed using the Investigator's Global Assessment (IGA) scale,which is a 5-point scale (from 0 =no disease to 4=severe disease) based on Simpson et al. 2020, IGA for atopic dermatitis (see Table 4; Simpson et al. 2020).~The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions at a given timepoint. It is not necessary that all characteristics under morphological description are present. Excoriations should not be considered when assessing disease severity.
Study NCT05435638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-001 1% cream 12 weeks treatment
Description: KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinician global impression of severity (CGI-S)
Description: Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Description: The VAS score will be collected on every in-clinic visit during the treatment period (Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.).~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?